Predictors of long-term high on-treatment platelet reactivity in clopidogrel-treated patients undergoing coronary stenting for acute coronary syndrome

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1565-1566

  Cuisset, Thomas ^a,b,c   Quilici, Jacques ^a,b,c   Morange, Pierre Emmanuel ^a,b,c   Bonnet, Jean Louis ^a,b,c   Alessi, Marie Christine ^a,b,c  

^a TIMONE HOSPITAL   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Acute coronary syndrome; Clopidogrel response; PRI VASP

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CORONARY STENT; CYP2C19 GENE; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE; GENE IDENTIFICATION; GENOTYPE; HETEROZYGOSITY; HOSPITAL DISCHARGE; HUMAN; LETTER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ACUTE CORONARY SYNDROME; CLOPIDOGREL RESPONSE; PRI VASP;

ACUTE CORONARY SYNDROME; AGED; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885321791     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.12.062     Document Type: Article

References (9)

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability In Individual responsiveness to clopidogrel clinical Implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-16.
2. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance Is associated with Increased risk of recurrent atherothrombotic events In patients with acutemyocardial Infarction. Circulation 2004;109:3171-5.
3. Cuisset T, Frere C, Quilici J, et al. high post-treatment platelet reactivity Identified low-responders to dual antiplatelet therapy at Increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-9.
4. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-7.
5. Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 2009;5:325-9.
6. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding In patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250-6.
7. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time In patients treated with percutaneous coronary Intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:2474-83.
8. Cuisset T, Quilici J, Loosveld M, et al. Comparison between Initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and Influence on clinical outcomes. Am Heart J 2012;164(3):327-33.
9. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high onclopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the Importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011;4:403-10.